• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bioassay development for ultrasensitive detection of influenza A nucleoprotein using digital ELISA

tetano

Editor, Senior Moderator
Anal Chem. 2016 Aug 4. [Epub ahead of print]
[h=1]Bioassay development for ultrasensitive detection of influenza A nucleoprotein using digital ELISA.[/h] Leirs K, Tewari Kumar P, Decrop D, P?rez Ruiz E, Leblebici P, Van Kelst B, Compernolle G, Meeuws H, Van Wesenbeeck L, Lagatie O, Stuyver L, Gils A, Lammertyn J, Spasic D.
[h=3]Abstract[/h] Flu is caused by the influenza virus that, due to mutations, keeps our body vulnerable for infections, making early diagnosis essential. Although immuno-based diagnostic tests are available, they have low sensitivity and reproducibility. In this paper, the prospect of detecting influenza A virus using digital ELISA has been studied. To appropriately select bioreceptors for this bioassay, seven commercial antibodies against influenza A nucleoprotein were methodically tested for their reactivity and binding affinity. The study has been performed on two markedly different platforms, being an enzyme-linked immunosorbent assay and a surface plasmon resonance system. The selected antibodies displayed completely different behavior on the two platforms and in various assay configurations. Surprisingly, the antibodies that showed overall good reactivity on both platforms had the highest dissociation constant among the tested antibodies, suggesting that, although important, binding affinity is not the only parameter to be considered when selecting antibodies. Moreover, only one antibody had the capacity to capture nucleoprotein directly in lysis buffer used for releasing this viral protein, which might pose huge advantage when developing assays with fast time-to-result. This antibody was implemented on an in-house developed digital ELISA platform for ultrasensitive detection of recombinant nucleoprotein, reaching a detection limit of 4 ? 1 fM in buffer and 10 ? 2 fM in 10 fold diluted nasopharyngeal swabs which is comparable to currently available fast molecular detection techniques. These results point to a great potential for ultrasensitive immuno-based influenza detection.


PMID: 27487722 DOI: 10.1021/acs.analchem.6b00502
[PubMed - as supplied by publisher]
 
Back
Top Bottom